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Oral vaccination with BCG provides protective systemic immunity against pathogenic
mycobacterial challenge. In this study, the anatomical distribution of Mycobacterium bovis
BCG following oral vaccination was investigated. Replicating bacteria in the Peyer’s patches
and mesenteric lymph nodes were present as solitary rods or clusters of two to three bac-
teria, the majority of which were isolated ex vivo as extracellular forms. Only a minority
were shown to be associated with typical antigen-presenting cells. Acid-fast staining of
mast cell granules in lymphoid tissues revealed a potential pitfall for these analyses and
may explain previous reports of acid-fast ‘coccoid’ forms of mycobacteria in tissues.
Crown Copyright  2012 Published by Elsevier Ltd. All rights reserved.Introduction
Tuberculosis (TB) is a worldwide disease of considerable mor-
tality and morbidity with 8.8 million incident cases and 1.4 mil-
lion deaths in 2010 [1]. BCG is the only available vaccine and is
routinely administered intradermally; however, recent studies
have highlighted the potential of the mucosal route of delivery
of BCG [2–5]. In particular, oral vaccination offers the advanta-
ges of ease of application with equivalent, or enhanced T-cell
responses, above that achieved with intradermal vaccination
[3]. Furthermore, oral vaccination is the only practical solution
available for controlling TB in domestic animals and/or wildlife
vectors of veterinary mycobacterial disease.
In previous reports, the anatomical distribution of orally
administered BCG within the lymphoid and non-lymphoid or-
gans of mice was investigated [2,4]. Following oral administra-
tion, BCG seeds the gastrointestinal tract lymphatics,ight  2012 Published by
; fax: +64 3 4798540.
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stituto Nacional de Tecnincluding the cervical, gastric and mesenteric lymph nodes,
and Peyer’s patches. Although BCG-reactive T-cells are
thought to be stimulated within the mucosal lymphatic sys-
tem, the majority of responding T-cells lack mucosal homing
markers and are present in the spleen as a pool of CD4 and
CD8 T-cells with IFN-c secreting potential. Reactive T-cells
possess the b1-integrin subunit—potentially involved in hom-
ing to the lung [4].
Despite these advances into understanding T-cell re-
sponses following oral BCG vaccination, mechanistic data is
still lacking on the interaction of BCG with antigen presenting
cells (APC). Mycobacteria are thought to exist in a transiently
intracellular state in the host, with both intracellular [6–8]
and extracellular [7,9,10] phases identified. BCG is effectively
internalized into neutrophils, macrophages and dendritic
cells [6,7,11]. However, direct infection of antigen presenting
cells (APC) is not required for antigen presentation [8,11,12].Elsevier Ltd. All rights reserved.
ologı´a Agropecuaria (INTA), Hurlingham, Buenos Aires, Argentina.
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of co-stimulator molecule and IL-12 expression and increases
the susceptibility of infected APC to apoptosis, compared with
uninfected APC [6,8]. Instead, soluble products produced from
live mycobacteria, or infected cells, are sufficient for the
induction of immune responses induced by uninfected APC
[4,8,13,14]. In this report, the anatomical distribution of BCG
within the mucosal lymphoid tissues has been investigated.
The data shows that following oral administration, BCG is
present in mucosal lymphatic tissue in a predominantly
extracellular form, with evidence for limited intracellular
persistence.
Methods
Lipid formulation
BALB/c mice were fed lipid encapsulated BCG Pasteur 1173
(2 · 107 CFU/dose) as previously described [4] and sacrificed at
12 weeks post-vaccination. In other experiments, mice were in-
jectedsubcutaneously (SC) into thescruff of theneckwith106 col-
ony CFU of BCG and sacrificed 2 weeks later. To optimize antibody
detection techniques, BCG (107 CFU) was administered intrave-
nously (IV) in 100 ll PBS and the mice were sacrificed after 6 h
for processing of the spleen for immunohistochemistry (IHC).
In some in vitro experiments, uptake of GFP-labeled BCG [15]
was determined in bone marrow-derived dendritic cell and
macrophages as previously described [4].
Isolation of cells from lymphatic tissue
Isolated mesenteric lymph nodes and Peyer’s patches were
teased apart in the presence of 20 lg/ml/DNaseI, followed by
digestion with 0.5 mg/ml collagenase P (Roche, Auckland,
NZ) in Hank’s buffered salt solution (HBSS) for 25 min at
37 C + 5% CO2 in a tube rotator [16]. After 25 min incubation,
200 ll 0.5 M EDTA (pH 7.2) was added and remaining frag-
ments were pressed through a 70 lm sieve. The preparation
was topped up to 50 ml with ice-cold Wuerzburger buffer
(Ref. [16]; PBS, 0.3% BSA, 5 mM EDTA and 20 lg/ml DNaseI).
Leukocytes and intracellular BCG were pelleted at 515g. The
remaining supernatant (containing bacteria and less that 1%
of total leukocytes; data not shown) was pelleted at 3220g
for 30 min at room temperature. CFU determinations were
performed on 7H11 agar [4].
Fluorescent associated cell sorting (FACS)
Isolated cells were labeled with unconjugated F4/80 (Prof. S.
Gordon, Oxford, UK), detected with goat anti-rat-PE (Jackson
Immunoresearch, Cat#712–116-153) and CD11c-PE (BD Biosci-
ences, Auckland, NZ) at 5 lg/ml. Cells were sorted according
to previously established protocols [16] on a Becton Dickinson
FACSaria.
Immunohistochemistry and confocal microscopy
Frozen tissue sections were fixed in 3% paraformaldehyde
(PFA; SIGMA, Auckland, NZ) in PBS for 10 min, or 75%acetone/25% ethanol for double labeling immunohistochemis-
try. PFA treated slides were quenched with 100 mM glycine/PBS
and blocked for 10 min with 5% goat serum in PBS. Biotinyla-
ted-CD11c (5 lg/ml; clone HL3) or biotinylated-CD11b (5 lg/
ml; both BD Biosciences, Auckland, NZ) in 100 ll 1% goat serum
was applied and slides incubated for 30 min. Slides were
washed with PBS/0.05% Tween-20 and antibodies were de-
tected with 50 ll of 1/200 streptavidin–ALP (Mabtech
Cat#3310–10) in TBS and slides incubated for 30 min. After
incubation, slideswere washed oncewith TBS and stained cells
visualized with Vector blue substrate (Vector #SK-5300) pre-
pared according to manufacturer’s instructions and incubated
for 15 min. Anti-rabbit–anti-BCG (Biogenesis, Poole, UK) was
then applied and detected in the next step with goat anti-rabbit
HRP (Sigma Cat. #A0545; 1/100 in PBS) and AEC substrate (Ref.
[16]; Sigma, Auckland, NZ). Stained sections were analyzed
using an Olympus BX51 microscope with a mounted Olympus
DP70 camera using bright field and differential interference
contrast. For confocal microscopy, biotinylated-Thy1.2 anti-
body (clone 30-H12, ATCC, Manassas, VA) was detected with
Alexa-488-streptavidin (Invitrogen Cat. #S11223) and the anti-
BCG antibody was detected using anti-rabbit Alexa Fluor 594
(Invitrogen Cat. #A11035). Cover slips were mounted using Pro-
long Gold (Invitrogen Cat. #P36930) according to manufac-
turer’s instructions and sections visualized using a Zeiss 510
confocal microscope. Ice-cold HBSS washes of the peritoneal
cavity of BALB/c mice were used to obtain mast cells. Mast cells
were detected on cytospin slides using naphthol AS-D chloro-
acetate (SIGMA, Auckland, NZ) according to Leder [17] and nu-
clei counterstained with hematoxylin.
Plating and most probable number assay
Lymph nodes or Peyer’s patches were aseptically removed
from sacrificed mice. Isolated tissue was transferred into a
well containing 1 ml of 7H9-SD (7H9 with 0.1% saponin,
20 lg/ml DNAse-I). Tissue was then teased out in single cell
suspensions using sterile forceps and further macerated
using a plunger of a 10 ml syringe and cells disrupted by vig-
orous pipetting through a 23-gauge needle and re-suspended
in 1 ml of 7H9-SD. Fifty microliters of each dilution (101–109)
was transferred into five wells containing 150 ll 7H9 and incu-
bated for at least 5 days at 37 C + 5% CO2. Plates were read
every day up to 25 days. Most probable numbers were calcu-
lated using the table provided from the US Food and Drug
Administration (FDA), source: http://www.fda.gov/Food/
ScienceResearch/LaboratoryMethods/BacteriologicalAnalyti-
calManualBAM/ucm109656.htm#tab3.
Results
Fractionation of leukocyte-associated and extracellular BCG
from mesenteric lymph nodes
In order to determine the cellular localization of BCG within
the mesenteric lymph node, differential centrifugation was
performed to fraction leukocyte-internalized BCG from extra-
cellular BCG. Cells were then sorted using FACS and antigen-
presenting cell subsets lysed prior to CFU determination. As
Fig. 1 – Extracellular location of BCG within mucosal
lymphoid tissue. (A) Cell suspensions were labeled with
CD11c and F4/80 and sorted by FACS into the indicated
subsets. Isolated cells were then lysed in saponin and
plated onto 7H11 agar for CFU enumeration, together with
the leukocyte-depleted (leukocyte-free) fraction for
comparison. (B) Equal proportions of mesenteric lymph
node cell suspensions, or in vitro cultured BCG at mid-log
phase were enumerated using solid agar (CFU) or broth
culture (MPN). (C) Effect of collagenase on viability of DC.
Bone marrow-derived DC were incubated with 0.5 mg/ml
collagenase for 25 min. Propidium iodide was then added
and viability determined by flow cytometry. (D) Effect of
collagenase on intracellular/extracellular fractionation of
BCG-infected DC preparations. Bone marrow-derived DC
was infected with BCG at a 1:1 MOI for 18 h. Preparations
were then fractionated by differential centrifugation into
leukocyte (DC) and leukocyte-free (DC-free) suspensions and
preparations enumerated for CFU on 7H11.
46 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 2 ( 2 0 1 3 ) 4 4 –5 0shown in Fig. 1A, the majority of BCG organisms present in
mesenteric lymph nodes fractionated into the leukocyte-free
fraction. It has previously been reported that resuscitation of
latent mycobacteria from host tissues is enhanced using li-
quid culture systems [18]. To ensure optimal recovery from
both leukocyte-free and leukocyte-bound fractions, the recov-
ery of BCG isolated from mLN (at 12 weeks post-vaccination)
was tested by comparing CFU enumeration on solid agar to
broth with most probable number (MPN) calculations. The re-
sults were compared to BCG grown to mid-log phase in vitro.
As shown in Fig. 1B, recovery of BCG from mLN was not en-
hanced by broth culture above that of CFU determination.
This suggests that the majority of BCG in mucosal lymphatic
tissue is amenable to CFU enumeration on solid agar. It was
possible that the tissue disaggregation procedure lysed APC
harboring BCG. To rule out possible harmful effects of collage-
nase on the integrity of plasma membranes of APC, dendritic
cells (see phenotype of Supplementary figure) were exposed
to collagenase and determined that viability was not affected
by collagenase exposure (Fig. 1C). In addition, collagenasetreatment of BCG-infected DC cultures did not enhance
BCG release from cell bound fractions (Fig. 1D).
Anatomical distribution of BCG within lymphoid tissues
In order to determine the cellular localization of BCG in
mucosal lymphatic tissue, an antibody-based technique was
employed, with reported sensitivities exceeding that of acid-
fast stain by several log [19]. The technique was first tested
on spleens from mice sacrificed 6 h after receiving 107 BCG
IV. As shown in Fig. 1A, BCG were readily visualized in the
spleen as rods—their appearance slightly ‘fattened’ by the
deposition of AEC substrate. Applying this technique to
Peyer’s patches and mesenteric lymph nodes, the extreme
paucity of bacteria in individual Peyer’s patches (Fig. 2D and
E) or mesenteric lymph nodes (Fig. 2B and F) was first
noted—with a maximum of only one to three bacteria visible
on a selection of sections prepared from each organ. Using
double labeling immunohistochemistry, it was possible to la-
bel both BCG and host APC. The results highlight the variety
of BCG interactions with cells of the mucosal tissues. BCG typ-
ically formed small groups of 1–3 rods present in both intra-
cellular and extracellular locations. Interestingly, BCG was
present as extracellular forms in T-cell-dependent areas, as
shown in Thy1.2 labeling in the confocal image (Fig. 2F).
Identification of mycobacterial ‘coccoid forms’ as mast cell
granules
When an attempt was made to confirm the results using
acid-fast staining, typical BCG organisms could not be reli-
ably identified in lymphoid tissues of orally vaccinated mice.
Instead, aggregates of intracellular acid-fast ‘coccoid struc-
tures’ were visible in the mesenteric lymph nodes of orally
vaccinated mice. Acid-fast positive ‘coccoid structures’ were
also present in peripheral lymph nodes (brachial/axillary) of
mice primed 2 weeks previously with BCG. In peripheral
lymph nodes, cells harboring these coccoid structures were
in proximity to the sub-capsular sinus (Fig. 3), yet failed to
label with CD169, ruling out their identity as sub-capsular
macrophages (data not shown). When lymphoid tissue was
examined by electron microscopy, it became apparent that
the coccoid structures were actually mast cell granules, as
shown by the evidence presented in Fig. 3D. To further con-
firm that the Ziehl–Neelsen stain was labeling mast cell
granules, mast cells were isolated from the peritoneal cavi-
ties of mice. As shown in Fig. 3E, acid-fast carbol fuchsin la-
beled mast cells in peritoneal cell washes with a similar
intensity to those stained with the classical mast cell ester-
ase stain (Fig. 3F).Discussion
Although progress has been made in recent years with regard
to understanding the role of T-cell-mediated responses in
immunity to mycobacteria, determining how mycobacterial
antigens are sampled and presented by the immune system
remains a challenging field. Extracellular mycobacteria have
been highlighted as the predominant surviving form that
Fig. 2 – Location of BCG within mesenteric lymph nodes and Peyer’s patches. (A) BCG rod within a leukocyte, orientated
proximal to the luminal aspect of a Peyer’s patch from a BCG-orally vaccinated mouse. (B) BCG rods within mesenteric lymph
node observed using differential interference contrast to enhance the contrast of plasma membranes of adjacent leukocytes.
(C) Double-labeling IHC technique performed on splenic tissue: frozen spleen sections of mice inoculated IV 6 h previously
with 106 BCG were labeled with F4/80 followed by anti-BCG anti-serum. (D and E) Double labeling of Peyer’s patch with CD11c
and anti-BCG. (D) Low power view with the location of BCG rods shown in (E) arrowed. (E) Note the location of rods within a
cell staining weakly for CD11c. (F) Merged confocal image of BCG rod between the membranes of Thy1.2+ labeled T-cells in a
mesenteric lymph node from an orally vaccinated mouse.
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changes, possess an inherently drug-resistant state [9,10]. In
this study, it has been shown that BCG colonization of mesen-
teric lymphatic tissue occurs in a predominantly extracellular
fashion, with a small number (1–3) of bacilli present at eachsite. This is in contrast to in vitro observations of infection
of antigen-presenting cells, e.g. DC or macrophages (Supple-
mentary figure) with BCG. Although it has been previously
observed that BCG colonization of the spleen results in an in-
flux of inflammatory CD11b+ cells or granuloma formation,
Fig. 3 – Coccoid structures within Ziehl–Neelsen labeled mesenteric and peripheral lymph nodes are mast cell granules. (A)
Acid fast (AF) structures with the mesenteric lymph node of an orally vaccinated mouse (arrowed) or within a cervical lymph
node of a SC vaccinated mouse (B and C). Note the proximity of the acid fast cells to the sub-capsular sinus. (D) Transmission
electron microscopic image of coccoid structures within the cervical lymph node of a SC vaccinated mouse. (E and F) Acid fast
(E) or chloroacetate (F) labeling of mast cells within peritoneal wash cell suspensions confirms acid fast labeling of mast cell
granules.
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influx of CD11b+ cells into areas of the Peyer’s patch or mes-
enteric lymph nodes containing BCG [8].
The absence of an association of BCG with typical antigen-
presenting cells within mucosal lymphoid tissue is not sur-
prising given recent findings that the presentation of BCG
antigens occurs independently of intracellular infection of
antigen-presenting cells [8]. Rothfuchs et al. [8] found that
IL-12 p40 was predominantly released from splenic DC that
did not contain intracellular BCG. Furthermore, their in vitro
studies showed that infected DC products could stimulate
non-infected DC in trans. Another study has demonstrated a
role for neutrophils in containing cutaneously administeredBCG [12], with in vitro evidence for the transfer of BCG from
neutrophils to DC [11].
It was previously shown that oral vaccination with lipid-
encapsulated BCG leads to the formation of reservoirs of BCG
within the alimentary tract lymphatics, with the highest
numbers of replicating bacteria associated with the mesenteric
lymph nodes and Peyer’s patches 12 weeks post-vaccination.
This time point coincides with the induction of maximal pro-
tective immunity [2]. In the present study, BCG persisted in
groups of 1–3 extracellular rods that were excluded from the
follicular area, but rather distributed in the T-cell-dependent
areas of mesenteric lymph nodes. In Peyer’s patches, BCG
was similarly present in inter-follicular areas, proximal to the
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lumen, it is possible that the lymphoid tissue analyzed is
not the site of replication of BCG, but rather that mesenteric
lymph nodes and Peyer’s patches act to capture BCG from
non-lymphoid sites within the gastrointestinal tract. How-
ever, the complete absence of cultivable BCG from the ilea
that have been resected free of lymphoid tissue argue against
a non-lymphoid origin for the replicating BCG within sites
(unpublished data). An interesting feature of BCG distribution
within these lymphoid sites is the predilection of BCG for
selected lymph nodes; for example, although BCG initially
seeds the spleen and gastric lymph nodes, it fails to replicate
in these sites and is absent at later time points [4]. In contrast,
replicating pools of BCG are found within cervical lymph
nodes, mesenteric lymph nodes and the Peyer’s patches [4].
This study confirmed a report published in the early 1960s
warning of possible confusion of mast cell granules with acid-
fast bacteria [20]. Mast cells are rich in metachromatic gran-
ules into which several common laboratory stains have been
shown to partition [20]. The source of mast cells in the lymph
nodes is likely via afferent lymph from mucosal [21] or
peripheral tissues [22] and are likely senescent or apoptotic
mast cells translocated from sites of inflammation [21]. Thus,
reports of coccoid forms of mycobacteria within solid tissues
[23] or peritoneal exudates [24] may need to be reinterpreted
in the light of this study.
In conclusion, this study demonstrates the complexity of
interactions between BCG and phagocytes within the gastroin-
testinal tract lymphatics. Further studies will be necessary to
determine the mechanism of BCG antigen presentation
in vivo; in particular, the relative roles of intracellular vs. extra-
cellular forms in the induction of immunity to mycobacteria.
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